Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease

[1]  K. Blennow,et al.  Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease , 2020, Translational Psychiatry.

[2]  H. Vanderstichele,et al.  Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis , 2020, Alzheimer's Research & Therapy.

[3]  W. M. van der Flier,et al.  Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology , 2020, Alzheimer's Research & Therapy.

[4]  W. M. van der Flier,et al.  ATN classification and clinical progression in subjective cognitive decline , 2020, Neurology.

[5]  C. Masters,et al.  Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis , 2020, Neurology.

[6]  G. Winterer,et al.  Plasma Amyloid Concentration in Alzheimer’s Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer’s Disease Cases from Controls , 2020, Journal of Alzheimer's disease : JAD.

[7]  A. Saykin,et al.  Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition , 2019, Alzheimer's & dementia.

[8]  K. Blennow,et al.  Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status , 2019, JAMA neurology.

[9]  P. Rossini,et al.  Plasma A (cid:2) 42 as a Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study , 2019 .

[10]  M. Carrillo,et al.  Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia , 2019, JAMA.

[11]  W. M. van der Flier,et al.  Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia , 2018, Alzheimer's & Dementia.

[12]  Y. Guan,et al.  Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease. , 2019, Journal of Alzheimer's disease : JAD.

[13]  A. Mauleon,et al.  Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI) , 2018, Alzheimer's Research & Therapy.

[14]  C. Glabe,et al.  Epitomic Characterization of the Specificity of the Anti-Amyloid Aβ Monoclonal Antibodies 6E10 and 4G8 , 2018, Journal of Alzheimer's disease : JAD.

[15]  W. M. van der Flier,et al.  Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes , 2018, Annals of neurology.

[16]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[17]  W. M. van der Flier,et al.  Amsterdam Dementia Cohort: Performing Research to Optimize Care , 2018, Journal of Alzheimer's disease : JAD.

[18]  W. M. van der Flier,et al.  Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. , 2018, Clinical chemistry.

[19]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[20]  C. Rowe,et al.  High performance plasma amyloid-beta biomarkers for Alzheimer's disease , 2018 .

[21]  Christina Patterson,et al.  World Alzheimer report 2018 , 2018 .

[22]  A. Ruiz,et al.  Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer’s Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study , 2018, The Journal of Prevention of Alzheimer's Disease.

[23]  C. Masters,et al.  Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals , 2017, Alzheimer's & dementia.

[24]  James G. Bollinger,et al.  Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.

[25]  C. Humpel.  Platelets: Their Potential Contribution to the Generation of Beta-amyloid Plaques in Alzheimer's Disease. , 2017, Current neurovascular research.

[26]  Johannes Kornhuber,et al.  Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease , 2016, Journal of Alzheimer's disease : JAD.

[27]  K. Blennow,et al.  Plasma β-amyloid in Alzheimer’s disease and vascular disease , 2016, Scientific Reports.

[28]  H. Vanderstichele,et al.  Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes , 2016, Journal of Alzheimer's disease : JAD.

[29]  H. Struyfs,et al.  Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis. , 2015, Journal of Alzheimer's disease : JAD.

[30]  Miles Miller,et al.  Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits , 2014, PloS one.

[31]  Andrew J. Saykin,et al.  A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[32]  H. Kit.  Enabling Ultrasensitive Protein Quantification with the Quanterix Homebrew Kit , 2014 .

[33]  David M. Rissin,et al.  Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations , 2010, Nature Biotechnology.

[34]  W. M. van der Flier,et al.  Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. , 2010, Clinical chemistry.

[35]  A. Kratz,et al.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. , 2004, The New England journal of medicine.

[36]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[37]  R.,et al.  Amyloid precursor protein processing and Ab42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .